{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "5-FU",
      "BCC nevus syndrome",
      "Hedgehog signaling cascade",
      "Mohs surgery",
      "Toll-like receptor",
      "actinic keratosis",
      "basal cell carcinoma",
      "condylomata accuminata",
      "cytokines",
      "field cancerization",
      "imiquimod",
      "immunosuppression",
      "inflammation",
      "interferon",
      "nonmelanoma skin cancer",
      "organ transplantation",
      "photodynamic therapy",
      "radiation",
      "skin aging",
      "sun exposure"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "26450707",
  "DateCompleted": {
    "Year": "2016",
    "Month": "09",
    "Day": "09"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "12",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2015",
        "Month": "10",
        "Day": "09"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.2217/fon.15.192"
    ],
    "Journal": {
      "ISSN": "1744-8301",
      "JournalIssue": {
        "Volume": "11",
        "Issue": "22",
        "PubDate": {
          "Year": "2015",
          "Month": "Nov"
        }
      },
      "Title": "Future oncology (London, England)",
      "ISOAbbreviation": "Future Oncol"
    },
    "ArticleTitle": "Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.",
    "Pagination": {
      "StartPage": "2985",
      "EndPage": "2990",
      "MedlinePgn": "2985-90"
    },
    "Abstract": {
      "AbstractText": [
        "Imiquimod, a TLR7 agonist, is a novel immune response modifier currently widely used in the treatment of actinic keratoses (in situ squamous cell carcinoma). Imiquimod has revolutionized the treatment of field cancerization and has been approved for the treatment of superficial basal cell carcinoma with the recommendation of a 6-week treatment strategy, offering an alternative to surgery or other destructive treatment strategies."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Dermatology & Venerology, A Syggros Hospital, University of Athens, Medical School, 5, I. Dragoumi Str. 16121 Athens, Greece."
          }
        ],
        "LastName": "Papakostas",
        "ForeName": "Dimitrios",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Dermatology, Venerology & Allergology, Catholic Clinic Bochum, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44971 Bochum, Germany."
          }
        ],
        "LastName": "Stockfleth",
        "ForeName": "Eggert",
        "Initials": "E"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Future Oncol",
    "NlmUniqueID": "101256629",
    "ISSNLinking": "1479-6694"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Aminoquinolines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunologic Factors"
    },
    {
      "RegistryNumber": "P1QW714R7M",
      "NameOfSubstance": "Imiquimod"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Topical"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Aminoquinolines"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "chemistry",
        "pharmacokinetics"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Carcinoma, Basal Cell"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Imiquimod"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "chemistry",
        "pharmacokinetics"
      ],
      "DescriptorName": "Immunologic Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Staging"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Product Surveillance, Postmarketing"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Skin Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}